[1]吴林耿,陈猛,苟庆,等.中性粒细胞/淋巴细胞比值对晚期肝细胞癌FOLFOX肝动脉灌注化疗近期疗效的影响[J].中国医学物理学杂志,2021,38(5):602-605.[doi:DOI:10.3969/j.issn.1005-202X.2021.05.015]
　WU Lingeng,CHEN Meng,et al.Effects of neutrophil to lymphocyte ratio on short-term efficacy of FOLFOX hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma[J].Chinese Journal of Medical Physics,2021,38(5):602-605.[doi:DOI:10.3969/j.issn.1005-202X.2021.05.015]
点击复制

中性粒细胞/淋巴细胞比值对晚期肝细胞癌FOLFOX肝动脉灌注化疗近期疗效的影响()
分享到：

《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]

卷:
38卷
期数:
2021年第5期
页码:
602-605
栏目:
医学影像物理
出版日期:
2021-05-01

文章信息/Info

Title:
Effects of neutrophil to lymphocyte ratio on short-term efficacy of FOLFOX hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
文章编号:
1005-202X（2021）05-0602-04
作者:
吴林耿1; 2; 陈猛1; 苟庆1; 麦启聪1; 周泽健1
1.广东省人民医院（广东省医学科学院）肿瘤中心介入治疗科， 广东 广州 510080； 2.汕头大学医学院， 广东 汕头 515041
Author(s):
WU Lingeng1;  2;  CHEN Meng1;  GOU Qing1;  MAI Qicong1;  ZHOU Zejian1
1. Department of Interventional Therapy, Cancer Center, Guangdong Provincial Peoples Hospital (Guangdong Academy of Medical Sciences), Guangzhou 510080, China 2. Medical College of Shantou University, Shantou 515041, China
关键词:
肝细胞癌; 中性粒细胞; 淋巴细胞; FOLFOX; 经导管动脉灌注化疗
Keywords:
Keywords: hepatocellular carcinoma neutrophil lymphocyte FOLFOX transcatheter arterial infusion chemotherapy
分类号:
R735.7
DOI:
DOI:10.3969/j.issn.1005-202X.2021.05.015
文献标志码:
A
摘要:
目的：探讨中性粒细胞/淋巴细胞比值（NLR）对晚期肝细胞癌（HCC）动脉灌注化疗近期疗效的影响。方法：回顾性收集分析2017年5月~2019年3月使用FOLFOX肝动脉灌注化疗的晚期HCC患者共92例。通过CT或MR比较患者每个治疗周期后肿瘤局部反应，通过相关检查结果及临床症状观察患者疗效及肝动脉灌注安全性等。结果：根据mRECIST标准对肝内病灶进行评价，NLR＜4.0组患者的客观缓解率显著高于NLR≥4.0组患者（41.5% vs 17.9%, P=0.016）。NLR＜4.0组患者的疾病控制率显著优于NLR≥4.0组（52.8% vs 28.2%；P=0.018）。对于肝内病灶，NLR＜4.0组的中位PFS（月）较NLR≥4.0组更长（6.1 vs 4.1, P=0.013）。针对全身肿瘤病灶进行疗效评估，NLR＜4.0组和NLR≥4.0组之间的中位PFS（月）也有显著差异（4.3 vs 3.1, P=0.022）。结论：使用FOLFOX肝动脉灌注治疗HCC安全性及有效性均较好，且NLR是预测HCC灌注化疗术后疗效的指标，术前高NLR的HCC患者治疗后PFS较短。
Abstract:
Abstract: Objective To investigate the effects of neutrophil to lymphocyte ratio (NLR) on the short-term therapeutic efficacy of FOLFOX hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (HCC). Methods A total of 92 patients with advanced HCC treated by FOLFOX hepatic arterial infusion chemotherapy from May 2017 to March 2019 were enrolled in the study. CT or MR was used to compare the local tumor response after each treatment cycle, and the therapeutic efficacy and safety of hepatic arterial perfusion were evaluated by relevant examination results and clinical symptoms. Results The intrahepatic lesions were evaluated according to mRECIST criteria. The objective response rate of NLR<4.0 group was significantly higher than that of NLR≥4.0 group (41.5% vs 17.9%, P=0.016). The disease control rate of NLR<4.0 group was also superior to that of NLR≥4.0 group (52.8% vs 28.2%, P=0.018). For intrahepatic lesions, the median progression free survival (PFS) in NLR<4.0 group was longer than that in NLR≥4.0 group (6.1 months vs 4.1 months, P=0.013) and the evaluation of the therapeutic efficacy of systemic tumor lesions showed that the median PFS was also significantly different between NLR<4.0 group and NLR≥4.0 group (4.3 months vs 3.1 months, P=0.022). Conclusion FOLFOX hepatic arterial infusion is safe and effective in treating HCC, and NLR is an indicator to predict the therapeutic efficacy of HCC perfusion chemotherapy. Patients with high NLR before surgery have shorter PFS after treatment.

相似文献/References:

[1]韩柱君,巩贯忠,路玉昆,等. 原发性肝细胞癌的CT影像组学分析[J].中国医学物理学杂志,2018,35(12):1426.[doi:DOI:10.3969/j.issn.1005-202X.2018.12.011]
　HAN Zhujun,GONG Guanzhong,LU Yukun,et al. CT radiomic features of primary hepatocellular carcinoma[J].Chinese Journal of Medical Physics,2018,35(5):1426.[doi:DOI:10.3969/j.issn.1005-202X.2018.12.011]
[2]闫冰,吴爱东,张洪波,等. 肝细胞癌共面和非共面容积旋转调强放疗与螺旋断层放疗的剂量学研究[J].中国医学物理学杂志,2019,36(8):877.[doi:DOI:10.3969/j.issn.1005-202X.2019.08.003]
　YAN Bing,WU Aidong,ZHANG Hongbo,et al. Dosimetric study on coplanar and noncoplanar volumetric modulated arc therapy and helical tomotherapy for hepatocellular carcinoma[J].Chinese Journal of Medical Physics,2019,36(5):877.[doi:DOI:10.3969/j.issn.1005-202X.2019.08.003]
[3]刘海峰,许永生,刘钊,等.钆塞酸二钠增强磁共振和弥散加权成像诊断肝细胞癌TACE术后存活或复发病灶的价值[J].中国医学物理学杂志,2020,37(5):561.[doi:10.3969/j.issn.1005-202X.2020.05.006]
　LIU Haifeng,XU Yongsheng,LIU Zhao,et al.Diagnostic value of Gd-EOB-DTPA enhanced MRI and DWI in residual or recurrent lesionsafter TACE for hepatocellular carcinoma[J].Chinese Journal of Medical Physics,2020,37(5):561.[doi:10.3969/j.issn.1005-202X.2020.05.006]
[4]魏佳赟,姚佳,李汛.细胞外基质刚度在肝细胞癌中的研究进展[J].中国医学物理学杂志,2021,38(6):770.[doi:DOI:10.3969/j.issn.1005-202X.2021.06.020]
　WEI Jiayun,YAO Jia,et al.Advances of research on extracellular matrix stiffness in hepatocellular carcinoma[J].Chinese Journal of Medical Physics,2021,38(5):770.[doi:DOI:10.3969/j.issn.1005-202X.2021.06.020]
[5]范义湘,易紫薇,胡煜麟,等.NIS基因转染对肝细胞癌NIS蛋白表达及摄碘功能的影响[J].中国医学物理学杂志,2021,38(10):1219.[doi:DOI:10.3969/j.issn.1005-202X.2021.10.007]
　FAN Yixiang,YI Ziwei,HU Yulin,et al.Effects of NIS gene transfection on NIS protein expression and iodine uptake in hepatocellular carcinoma[J].Chinese Journal of Medical Physics,2021,38(5):1219.[doi:DOI:10.3969/j.issn.1005-202X.2021.10.007]
[6]谢孟臻,吴斌,许立强,等.双层探测器光谱CT虚拟平扫中重建层厚对肝细胞癌显示的影响[J].中国医学物理学杂志,2022,39(12):1495.[doi:DOI:10.3969/j.issn.1005-202X.2022.12.007]
　XIE Mengzhen,WU Bin,XU Liqiang,et al.Effect of reconstructed slice thickness on the display of hepatocellular carcinoma in virtual non-contrast scan of dual-layer detector spectral CT[J].Chinese Journal of Medical Physics,2022,39(5):1495.[doi:DOI:10.3969/j.issn.1005-202X.2022.12.007]

备注/Memo

备注/Memo:
【收稿日期】2020-10-19 【作者简介】吴林耿，硕士，研究方向：肿瘤介入治疗，E-mail: walkerlgwu@163.com 【通信作者】周泽健，主任医师，研究方向：肿瘤介入治疗，E-mail: zhzejian@126.com
更新日期/Last Update: 2021-05-31